Michael King
Rodman & Renshaw Research

My name is Mike King. I am the senior biotechnology analyst at Rodman & Renshaw following the biotech sector and I had Director of Research here at Rodman. I've got the honor today of having a call with the esteemed Dr. Laura Esserman from UCSF, who I will introduce in a moment. We're going to be talking about Atossa's lead program, (Z)-endoxifen and its role in benefiting patients with breast cancer. Also on the call with me will be Steve Quay, who's the Founder, Chairman, CEO and President of Atossa. He will not be making any formal remarks, but if we need him to jump in, then we would be delighted to have him join us as well. So more...

Steven Quay
Chairman, CEO & President

So I will jump in and just say thank you, Mike. Okay. Thank you, Dr. Esserman, for joining you. This is -- I really appreciate this.

Michael King
Rodman & Renshaw Research

Now I can't see Laura. Let me just see if I can do this. I see [ Harrison ]. Laura, are you there? Can you say hello? Yes, I'm not seeing her. No. I'm not -- this is not working. Harrison, can you see if you can let her in? There we go. Success.

Laura Esserman

Well, I'm joining -- let me figure out how to get off this. I have a new -- okay. I have a new tool in my office that has a screen where I could just join directly, but it's not working. I mean, I could